ALK-Abelló A/S Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/5/2026)
| Balance Sheet | Total Assets | 9,172,000,000.00 | ROE | 70.27 % |
| Balance Sheet | Total Equity | 6,445,000,000.00 | ROA | 13.05 % |
| Cashflow | Capital Expenditures | -276,000,000.00 | P/FCF | 32.49 |
| Cashflow | Free Cash Flow | 1,541,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 1,817,000,000.00 | P/CF | 27.56 |
| Income | Earnings per Share (diluted) | 5.40 | Div. Yield | 0.71 % |
| Income | Net Income | 1,197,000,000.00 | P/E | 41.85 |
| Income | Shares Outstanding | 221,562,600.00 | P/B | 7.77 |
| Income | Total Revenue | 6,312,000,000.00 | P/S | 7.93 |
Ratios calculated on: 10/14/2026
Company Description
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.alk.net
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more